Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis

Institution:	1. Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892;2. Department of Pathology, Aichi Medical University School of Medicine, Nagakute, Japan 480-1195;3. Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland 80-210;4. Department of Pathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany 39106;5. Department of Pathology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland 01-138;6. Department of Tumor Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland 31-115;7. Department of Pathomorphology, Jagiellonian University, Krakow, Poland 31-007;8. Independent Laboratory of Pathology, Zdunomed, Szczecin, Poland 70-891;9. Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD 20892

Abstract:	ObjectiveProgrammed death ligand 1 (PD-L1) has been reported to be connected to prognosis in individuals with malignant pleural mesothelioma (MPM), although there is no consensus based on data from previous studies. Accordingly, this quantitative meta-analysis investigated prognostic and clinicopathological utility of PD-L1 in patients with MPM.MethodsA comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Library databases for articles published up to October 4, 2019 was performed. Studies using immunohistochemical techniques to detect/quantify the expression of PD-L1 in MPM tissue were enrolled in the analysis. The combined hazard ratio (HR) and corresponding 95% confidence interval (CI) was applied to assess the association between PD-L1 expression and overall survival (OS).ResultsA total of 11 studies comprising 1606 patients was included in the present meta-analysis. For OS, pooled data revealed an HR of 1.50 (95% CI 1.32–1.70; p < 0.001), suggesting that patients with PD-L1 overexpression experience inferior OS. Subgroup analysis revealed that elevated PD-L1 remained a significant prognostic indicator for worse OS, irrespective of sample size, cut-off value, ethnicity, and Newcastle-Ottawa Scale score. Moreover, PD-L1 overexpression was associated with non-epithelioid histology (odds ratio 4.30 95% CI 1.89–9.74]; p < 0.001).ConclusionsResults of this meta-analysis show that elevated expression of PD-L1 could be a factor predicting poorer survival in patients with MPM.

Keywords:	Programmed cell death ligand 1 Meta-analysis Immunotherapy Prognosis Malignant pleural mesothelioma PD-L1"} {"#name":"keyword" "$":{"id":"k0035"} "$$":[{"#name":"text" "_":"programmed death ligand 1 MPM"} {"#name":"keyword" "$":{"id":"k0045"} "$$":[{"#name":"text" "_":"malignant pleural mesothelioma IHC"} {"#name":"keyword" "$":{"id":"k0055"} "$$":[{"#name":"text" "_":"immunohistochemistry HR"} {"#name":"keyword" "$":{"id":"k0065"} "$$":[{"#name":"text" "_":"hazard ratio CI"} {"#name":"keyword" "$":{"id":"k0075"} "$$":[{"#name":"text" "_":"confidence interval OS"} {"#name":"keyword" "$":{"id":"k0085"} "$$":[{"#name":"text" "_":"overall survival NOS"} {"#name":"keyword" "$":{"id":"k0095"} "$$":[{"#name":"text" "_":"Newcastle-Ottawa Scale ICIs"} {"#name":"keyword" "$":{"id":"k0105"} "$$":[{"#name":"text" "_":"immune checkpoint inhibitors PD-1"} {"#name":"keyword" "$":{"id":"k0115"} "$$":[{"#name":"text" "_":"programmed death 1 APCs"} {"#name":"keyword" "$":{"id":"k0125"} "$$":[{"#name":"text" "_":"antigen-presenting cells TILs"} {"#name":"keyword" "$":{"id":"k0135"} "$$":[{"#name":"text" "_":"tumor-infiltrating immune cells PRISMA"} {"#name":"keyword" "$":{"id":"k0145"} "$$":[{"#name":"text" "_":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses OR"} {"#name":"keyword" "$":{"id":"k0155"} "$$":[{"#name":"text" "_":"odds ratio NCDB"} {"#name":"keyword" "$":{"id":"k0165"} "$$":[{"#name":"text" "_":"National Cancer Database PFS"} {"#name":"keyword" "$":{"id":"k0175"} "$$":[{"#name":"text" "_":"progression-free survival TC"} {"#name":"keyword" "$":{"id":"k0185"} "$$":[{"#name":"text" "_":"tumor cell
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏